Five things to know:
1. Quarterly revenue rose 2.5% year over year, according to a news release.
2. Medtronic’s neuroscience portfolio, which includes cranial and spinal technologies, saw a 4.4% year-over-year increase in revenue with $2.5 billion.
3. Cranial and spinal technologies saw $1.25 billion in sales, a 3.8% increase year over year. Growth was driven by adoption of the AiBLE ecosystem of enabling technologies.
4. Neuromodulation sales were $476 million, a 12% year-over-year increase.
5. Medtronic expects its fiscal year 2025 revenue to grow between 4.75% to 5% year over year.
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.
